Denver, Colorado (PRWEB) April 18, 2014
Zyme and Channelinsight have reached a resolution to their dispute regarding United States Patent No. 8,296,258 B2 (the "‘258 Patent").
Channelinsight will not assert the ‘258 Patent or any patent in the ‘258 Patent family against Zyme or Zyme’s existing or future customers. Channelinsight and Zyme look forward to competing in the marketplace.
Channelinsight, the industry leader and pioneer in channel data management, delivers a cloud-based application and enablement services providing manufacturers with visibility into every partner and every end-customer in every transaction, in real time – allowing them to gain the insight necessary to drive sales and optimize inventory. Channelinsight collects “raw” POS and inventory data from tens of thousands of channel partners globally, and processes over $120 billion in channel sales transactions annually. Customers benefiting from this 7x24x365 solution include: HP, TE Connectivity, AMD, Sharp Electronics, Microsoft, Smart Technologies, Corning Life Sciences, and more. Channelinsight is backed by Rho Ventures, Sequel Venture Partners and Vedanta Capital, and is headquartered in Denver, CO with offices in Palo Alto, CA, as well as globally. For more information on Channelinsight’s products and services, go to http://www.channelinsight.com.